Swiss National Bank held its position in Halozyme Therapeutics Inc. (NASDAQ:HALO) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 185,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Swiss National Bank owned about 0.14% of Halozyme Therapeutics worth $1,597,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HALO. IFP Advisors Inc boosted its stake in Halozyme Therapeutics by 300.8% in the first quarter. IFP Advisors Inc now owns 11,366 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 8,530 shares in the last quarter. Teachers Advisors Inc. boosted its stake in Halozyme Therapeutics by 357.1% in the first quarter. Teachers Advisors Inc. now owns 706,111 shares of the biopharmaceutical company’s stock worth $6,687,000 after buying an additional 551,645 shares in the last quarter. Franklin Resources Inc. boosted its stake in Halozyme Therapeutics by 22.2% in the first quarter. Franklin Resources Inc. now owns 2,219,933 shares of the biopharmaceutical company’s stock worth $21,022,000 after buying an additional 403,645 shares in the last quarter. BlackRock Group LTD boosted its stake in Halozyme Therapeutics by 11.2% in the first quarter. BlackRock Group LTD now owns 128,945 shares of the biopharmaceutical company’s stock worth $1,221,000 after buying an additional 12,956 shares in the last quarter. Finally, BlackRock Fund Advisors boosted its stake in Halozyme Therapeutics by 2.5% in the first quarter. BlackRock Fund Advisors now owns 4,302,729 shares of the biopharmaceutical company’s stock worth $40,747,000 after buying an additional 104,120 shares in the last quarter. 80.41% of the stock is owned by institutional investors.
Halozyme Therapeutics Inc. (NASDAQ:HALO) traded down 0.91% during trading on Monday, reaching $11.98. 882,979 shares of the company’s stock traded hands. Halozyme Therapeutics Inc. has a 1-year low of $6.96 and a 1-year high of $18.65. The firm’s market capitalization is $1.53 billion. The firm has a 50 day moving average of $10.55 and a 200 day moving average of $9.82.
Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.06. Halozyme Therapeutics had a negative net margin of 44.90% and a negative return on equity of 234.15%. The company earned $33.30 million during the quarter, compared to analysts’ expectations of $29.94 million. During the same quarter last year, the business earned $0.02 EPS. The business’s revenue was down 23.3% on a year-over-year basis. Equities analysts forecast that Halozyme Therapeutics Inc. will post ($0.91) EPS for the current year.
A number of analysts have recently commented on the stock. Piper Jaffray Cos. boosted their target price on shares of Halozyme Therapeutics from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Friday, September 16th. Wells Fargo & Co. reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, September 8th. Finally, Canaccord Genuity reissued a “buy” rating and set a $11.00 target price on shares of Halozyme Therapeutics in a research note on Monday, June 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $16.11.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.